Physician profile
Isaac Eisenstein
NPI 1780649830
$12,874.55
in general payments reported to CMS, 2019-2025
38 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,149 · 2020: $1,335 · 2021: $2,170 · 2022: $2,058 · 2023: $1,520 · 2024: $2,079 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,163.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,379.95 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,624.93 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,260.30 | 2019-2025 | Lifevest |
| Biotronik INC. | $811.92 | 2019-2023 | Acticor 7 Vr-T Dx |
| Edwards Lifesciences Corporation | $759.40 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $688.77 | 2021-2025 | Verquvo, Capvaxive, Winrevair |
| Abiomed | $612.62 | 2019-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $506.72 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $458.01 | 2019-2023 | Camzyos, Eliquis |
| Novo Nordisk INC | $413.10 | 2021-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $375.59 | 2019-2025 | Aveir, Cardiomems |
| Pfizer INC. | $349.64 | 2019-2025 | |
| Amgen INC. | $346.12 | 2019-2025 | Repatha, Repatha |
| Lantheus Medical Imaging, INC. | $311.95 | 2020-2025 | Definity |
| Cvrx, INC. | $275.17 | 2021-2024 | Barostim Neo System |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Eisenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.